Produksi Insulin Manusia Rekombinan

Bioteknologi bertemu manufaktur farmasi

Pharmaceutical & Drug Manufacturing Global Industrial Scale $35 billion

Ikhtisar

Recombinant human insulin is produced using genetically engineered Escherichia coli or Saccharomyces cerevisiae that express the human insulin gene. This biotechnological process replaced the previous method of extracting insulin from pig and cow pancreases, providing unlimited supply with reduced immunogenicity. The process involves fermentation, cell lysis, inclusion body solubilization, refolding, enzymatic modification, and multi-step chromatographic purification to produce pharmaceutical-grade insulin.

Proses Kimia

E. coli expressing proinsulin genes are fermented in large bioreactors. Inclusion bodies containing proinsulin are isolated, solubilized in urea, and the protein is refolded by controlled oxidation. Trypsin and carboxypeptidase B cleave the C-peptide to yield mature insulin, which is purified by reversed-phase and ion-exchange chromatography.

Proinsulin →[Trypsin + Carboxypeptidase B] Insulin (A-chain + B-chain linked by disulfide bonds) + C-peptide

Bahan Baku

  • Glucose (C₆H₁₂O₆) — Corn processing (Carbon source for fermentation)
  • Ammonium sulfate ((NH₄)₂SO₄) — Chemical synthesis (Nitrogen source)
  • Trypsin (enzyme) — Recombinant production (C-peptide cleavage)

Produk Akhir

  • Recombinant human insulin — Diabetes treatment (>98% purity, multiple analog forms)
<path stroke-linecap="round" stroke-linejoin="round" d="M12 9v3.75m-9.303 3.376c-.866 1.5.217 3.374 1.948 3.374h14.71c1.73 0 2.813-1.874 1.948-3.374L13.949 3.378c-.866-1.5-3.032-1.5-3.898 0L2.697 16.126zM12 15.75h.007v.008H12v-.008z" />

Environmental Impact

Fermentation-based production generates biological waste requiring sterilization before disposal. Chromatographic purification consumes significant water and buffer solutions. However, the environmental impact is far less than animal-sourced insulin which required millions of animal pancreases annually.

Pertimbangan Keselamatan

Inovasi Terbaru

Insulin analogs (lispro, glargine, aspart) with modified amino acid sequences provide faster or longer-acting profiles.
Cell-free protein synthesis and oral insulin delivery systems are in advanced development stages.

Lebih banyak di %(name)s Pharmaceutical & Drug Manufacturing

Produksi Amoksisilin Semi-Sintetik

Global Industrial Scale

Produksi Penisilin G dengan Fermentasi

Global Industrial Scale

Sintesis Aspirin melalui Asetilasi Asam Salisilat

Global Industrial Scale

Sintesis Ibuprofen — Proses Hijau BHC

Global Industrial Scale

Sintesis Metformin Hidroklorida

Global Industrial Scale

Sintesis Omeprazol untuk Penghambat Pompa Proton

Global Industrial Scale

Sintesis Parasetamol (Asetaminofen)

Global Industrial Scale

Frequently Asked Questions

What industry uses Produksi Insulin Manusia Rekombinan?
Produksi Insulin Manusia Rekombinan is used in the pharmaceutical & drug manufacturing sector at global industrial scale scale.
What process is involved in Produksi Insulin Manusia Rekombinan?
E. coli expressing proinsulin genes are fermented in large bioreactors. Inclusion bodies containing proinsulin are isolated, solubilized in urea, and the protein is refolded by controlled oxidation. Trypsin and carboxypeptidase B cleave the C-peptide to yield mature insulin, which is purified by rev
What is the economic significance of Produksi Insulin Manusia Rekombinan?
Produksi Insulin Manusia Rekombinan has a market value of $35 billion.
What is the environmental impact of Produksi Insulin Manusia Rekombinan?
Fermentation-based production generates biological waste requiring sterilization before disposal. Chromatographic purification consumes significant water and buffer solutions. However, the environmental impact is far less than animal-sourced insulin which required millions of animal pancreases annua
What raw materials are used in Produksi Insulin Manusia Rekombinan?
The main raw materials include: Glucose (C₆H₁₂O₆), Ammonium sulfate ((NH₄)₂SO₄), Trypsin (enzyme).